Previous accept carboplatin multidrug chemotherapy in patients with recurrent ovarian cancer Carboplatin and Paclitaxel weekly therapy is safe and effective

Taxol and carboplatin Joint effective treatment of advanced ovarian cancer According to an obstetrics and gynecology oncology groups (GOG) study said that the smaller Phase III epithelial ovarian cancer patients, ca...

P53 gene can cure ovarian cancer Abstract: a group P53 mutations in the genes in patients with advanced ovarian cancer by more cycles of P53 gene therapy and chemotherapy, r...

Kikuchi, the Japanese report, have received platinum multidrug chemotherapy for recurrent ovarian cancer Japanese women, a weekly carboplatin and paclitaxel chemotherapy in a meeting, can significantly prolong survival, and patients can be tolerated. (Int J Cancer YORK 2005,15:45)

The case control study included surgery and platinum-based adjuvant chemotherapy complete remission for at least 6 months after the recurrence of ovarian cancer patients. Of the 68 patients, 27 patients received a weekly meeting of Taxol and carboplatin chemotherapy (WTJ) (Group I), carboplatin (AUC area under the curve for 2) plus paclitaxel (80 mg/m2); The remaining 41 patients (Group II) to platinum-based (P ) other chemotherapy, 37 patients with CAP program, a monthly meeting of carboplatin and paclitaxel program four cases.

The first group and second group of neutropenia, thrombocytopenia and peripheral neuropathy occurred in 1.7% and 90%, 5.1% and 14.3% and 0% and 4.8%.

The first group and second group total remission rates were 81% and 58.5%, respectively, for the therapeutic index of 3.9 and 1.9, the median survival time was 48.3 months and 17.8 months (P <0.005).

Due to the use of taxanes and platinum-based first-line chemotherapy, and the treatment of choice in patients with relapsing increased, the past 10 years in patients with epithelial ovarian cancer prognosis has improved significantly. In addition, physicians, oncology and genetics consultant physicians to collaborate to identify family syndrome, the implementation of risk reduction strategies, if selectively in some patients with bilateral tubal preventive ovary is a very ordinary thing. Although there is no effective ovarian cancer screening program, and CA125 protein group of dynamic methods of the future promising. From the perspective of treatment, gemcitabine, doxorubicin liposome and the occasional parked for Kang, as a first-line drug therapy study is ongoing. Intraperitoneal chemotherapy drug application line is also undergoing evaluation, application of drugs such as Taxol mitigation strategy also arouse concern. It has been found that many drugs used for the development of molecular targets, including p53, lysophosphatidic acid, BCL-2 family, epidermal growth factor (EGFR) and vascular endothelial growth factor receptor (VEGFR) - mediated pathway. In newly diagnosed patients and the only signs of relapse patients, or VEGFR inhibition of EGFR pathway of drug clinical trials are being designed. Finally, microarray gene expression profile that the application of judgment as a prognostic tool and help cancer patients understand the resistance mechanism. The application of these methods, hope to further improve the common lethal disease survival.

Intraperitoneal chemotherapy should be first-line therapy in ovarian cancer A large number of pre-clinical data and the right abdominal anatomy, physiology and biology of ovarian cancer have suggested that understan...

Cisplatin / paclitaxel chemotherapy in the treatment of ovarian cancer drug side effects Whitney physicians that cisplatin / paclitaxel chemotherapy in the treatment of ovarian cancer treatment should become the new standard. Ca...

Ovarian cancer screening, treatment and prevention of the Current Situation and Prospect Although ovarian cancer chemotherapy drug developed considerable progress has been made, but patients with ovarian cancer and the overall s...

Diagnostic Classification Surgery According to a medical examination and transvaginal ultrasound findings suspected ovarian cancer is often a laparotomy to be confir...

Treatment of ovarian cancer chemotherapy new program Researchers reported that the joint use of both cisplatin and paclitaxel chemotherapy drug for ovarian cancer achieved better clinical remis...

Recurrent ovarian cancer chemotherapy new method - conventional chemotherapy drug efficacy forecast molecular targeted chemotherapy Ovarian cancer is the worst prognosis of gynecologic tumors. Patients with advanced epithelial ovarian cancer five-year survival rates gene...

CA-125 blood test results are forecast ovarian cancer the best indicators

Recurrent ovarian cancer may reoperation